COGNITION THERAPEUTICS INC
COGNITION THERAPEUTICS INC (CGTX): 23 pipeline candidates · 2 upcoming catalysts · ~18 mo cash runway · 29 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
17.6 months
D/E 0.21 · 0% dilution
Lead: Phase 3
23 candidates
2 upcoming, next in ~531d
3 buys · 0 sells (180d)
A transparent, data-derived signal for COGNITION THERAPEUTICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$127.1M
Cash
$31.2M
Quarterly Burn
$5.5M
Runway
17.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (23 candidates)
| Drug | Phase |
|---|---|
| Bupivacaine Injection [Marcaine] | Phase 3 |
| ct1812 | Phase 2 |
| Dexamedomedine | Phase 4 |
| Dexmedetomidine | Phase 4 |
| Dexmedetomidine and Midazolam | Phase 4 |
| Dexmedetomidine and Midodrine | Phase 4 |
| Dexmedetomidine infusion | Phase 4 |
| Dexmedetomidine Injection [Precedex] | Phase 4 |
| Fentanyl- midazolam | Phase 4 |
| golexanolone | Phase 1/Phase 2 |
Showing 10 of 23 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
73
Total value held
$17.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 6,003,574 | $4.6M |
| bios capital management, lp | 6,000,000 | $4.6M |
| davenport & co llc | 2,892,808 | $2.2M |
| renaissance technologies llc | 1,117,136 | $848K |
| blackrock, inc. | 968,362 | $735K |
| geode capital management, llc | 920,208 | $699K |
| hilton capital management, llc | 548,950 | $417K |
| vanguard fiduciary trust co | 463,684 | $352K |
| cm management, llc | 400,000 | $304K |
| jane street group, llc | 370,140 | $281K |
Showing top 10 of 73 institutional holders of COGNITION THERAPEUTICS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in COGNITION THERAPEUTICS INC's pipeline?
COGNITION THERAPEUTICS INC (CGTX) has 23 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is COGNITION THERAPEUTICS INC's lead drug candidate?
COGNITION THERAPEUTICS INC's most advanced tracked candidate is Bupivacaine Injection [Marcaine] (Phase 3) for Breast Cancer Female.
What is COGNITION THERAPEUTICS INC's next catalyst?
COGNITION THERAPEUTICS INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Postoperative Dexmedetomidine (PODEX) for Enhanced Recovery in Bowel Surgery: A Double-Blinded, Rand" — expected December 1, 2027.
What is COGNITION THERAPEUTICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, COGNITION THERAPEUTICS INC has approximately 17.6 months of cash runway.
What is COGNITION THERAPEUTICS INC's market capitalization?
COGNITION THERAPEUTICS INC's market capitalization is approximately $127.1M.
Get the full picture on COGNITION THERAPEUTICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.